Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “QL1706”

113 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 113 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07515469
What this trial is testing

A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD-1/Anti-CTLA-4 Bispecific Antibody, in Resectable Stage IB and IIA Hepatocellular Carcinoma With High Recurrence Risk

Who this might be right for
HCC - Hepatocellular CarcinomaIparomlimab and Tuvonralimab InjectionNeoadjuvant Immunotherapy
Tianjin Medical University Cancer Institute and Hospital 30
Testing effectiveness (Phase 2)Looking for participantsNCT07389629
What this trial is testing

Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC

Who this might be right for
Iparomlimab and TuvonralimabClear Cell Renal Cell CarcinomaNeoadjuvant Therapy
Sun Yat-sen University 25
Testing effectiveness (Phase 2)Looking for participantsNCT06908382
What this trial is testing

Neoadjuvant QL1706 Therapy for ESCC

Who this might be right for
Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
Shandong Provincial Hospital 32
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07200947
What this trial is testing

A Phase II Study of QL1706 and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Non-Small Cell Lung Cancer.

Who this might be right for
SMARCA4-Deficient TumorLocally Advanced or Metastatic Non-Small Cell Lung Cancer
Zhijie Wang 28
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07509515
What this trial is testing

QLC5513 Alone or in Combination With QL1706 in Previously Treated Advanced or Metastatic TNBC.

Who this might be right for
Triple-negative Breast Cancer (TNBC)
Fudan University 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT07138885
What this trial is testing

A Phase II, Single-Arm, Prospective Trial on the Efficacy and Safety of QL1706 Combination Regimen as Second-Line Therapy for Targeted-Immunotherapy-Resistant Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma (HCC)Second Line Treatment
Sun Yat-sen University 62
Testing effectiveness (Phase 2)Looking for participantsNCT06911684
What this trial is testing

Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC.

Who this might be right for
Rectal Cancer Patients
Sun Yat-sen University 88
Early research (Phase 1)Not Yet RecruitingNCT06822985
What this trial is testing

QL1706 As Second-line Treatment in Patients with Advanced Hepatocellular Carcinoma

Who this might be right for
HCC - Hepatocellular Carcinoma
Wan-Guang Zhang 21
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07407452
What this trial is testing

Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian Cancer

Who this might be right for
Ovarian Cancers
Jiangsu Cancer Institute & Hospital 50
Testing effectiveness (Phase 2)UnknownNCT05557565
What this trial is testing

A Phase II Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Cervical Cancer

Who this might be right for
Cervical Cancer
Qilu Pharmaceutical Co., Ltd. 150
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06852456
What this trial is testing

QL1706 in Combination With Neoadjuvant Chemotherapy Versus Neoadjuvant Chemotherapy for Locally Advanced, Resectable Esophageal Squamous Cell Carcinoma

Who this might be right for
Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
Qilu Pharmaceutical Co., Ltd. 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07315035
What this trial is testing

QL1706-SOX vs SOX Alone as Neoadjuvant Therapy for Resectable Diffuse-Type Gastric Cancer

Who this might be right for
Gastric Cancer Stage III
The First Affiliated Hospital with Nanjing Medical University 74
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07246317
What this trial is testing

Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer

Who this might be right for
Breast Cancer
Tianjin Medical University Cancer Institute and Hospital 188
Large-scale testing (Phase 3)Looking for participantsNCT05487391
What this trial is testing

QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Qilu Pharmaceutical Co., Ltd. 632
Testing effectiveness (Phase 2)Looking for participantsNCT06941766
What this trial is testing

Iparomlimab and Tuvonralimab (QL1706) for Intermediate Trophoblastic Tumors

Who this might be right for
Intermediate Trophoblastic Tumor
Peking Union Medical College Hospital 20
Testing effectiveness (Phase 2)UnknownNCT05603039
What this trial is testing

A Phase Ib/II Trial to Evaluate the Safety and Efficacy of QL1706 in Patients With Advanced Hepatocellular Carcinoma

Who this might be right for
Advanced Liver Cancer
Qilu Pharmaceutical Co., Ltd. 80
Testing effectiveness (Phase 2)Looking for participantsNCT07330596
What this trial is testing

QL1706 Combined With Chemotherapy in the Treatment of Immune-mediated NSCLC

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)
Anhui Provincial Cancer Hospital 96
Testing effectiveness (Phase 2)Looking for participantsNCT07530445
What this trial is testing

Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer

Who this might be right for
Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer
Sun Yat-sen University 40
Testing effectiveness (Phase 2)UnknownNCT05179317
What this trial is testing

Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy With or Without Bevacizumab in Women With Recurrent, or Metastatic Cervical Cancer

Who this might be right for
Cervical Cancer
Qilu Pharmaceutical Co., Ltd. 60
Testing effectiveness (Phase 2)UnknownNCT05329025
What this trial is testing

QL1706 Combined With Chemotherapy in Advanced Non-small Cell Lung Cancer

Who this might be right for
Non-small-cell Lung Cancer
Qilu Pharmaceutical Co., Ltd. 100
Load More Results